Report of the NIH panel to define principles of therapy of HIV infection. MMWR Morb Mortal Wkly Rep. 1998; 47(RR-5):1-41.
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Morb Mortal Wkly Rep. 1998; 47(RR-5):43-82.
Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996; 271.1582-6
O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, Cohen AR, et al.. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996; 276.105-10
Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al.. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997; 126.946-54
Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB, et al.. Prognostic indicators for AIDS and infectious disease death in HIV-infected drug users: plasma viral load and CD4+ cell count. JAMA. 1998; 279.35-40
Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, et al.. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999; 5.83-9
Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, et al.. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998; 177.40-7
O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al.. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996; 334.426-31
O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med. 1997; 126.939-45
Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis. 1996; 174:704-12.
Cozzi Lepri A, Katzenstein TL, Ullum H, Phillips AN, Skinhoj P, Gerstoft J, et al.. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS. 1998; 12.1639-43
Galetto-Lacour A, Yerly S, Perneger TV, Baumberger C, Hirschel B, Perrin L, et al.. Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group. J Infect Dis. 1996; 173.1388-93
Goedert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, White GC 2d, et al.. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med. 1989; 321.1141-8
Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep. 1987; 36 (Suppl 1):1S-15S.
Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994; 32.292-300
Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990; 28.495-503
Fletcher MA, Baron GC, Ashman MR, Fischl MA, Klimas NG. Use of whole blood methods in assessment of immune parameters in immunodeficiency states. Diagn Clin Immunol. 1987; 5.69-81
Tollerud DJ, Brown LM, Clark JW, Neuland CY, Mann DL, Pankiw-Trost LK, et al.. Cryopreservation and long-term liquid nitrogen storage of peripheral blood mononuclear cells for flow cytometry analysis: effects on cell subset proportions and fluorescence intensity. J Clin Lab Anal. 1991; 5.255-61
Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer; 1997.83-300
Hastie TJ, Tibshirani RJ. Generalized additive models. London: Chapman and Hall; 1990.22-6
Kroner BL, Rosenberg PS, Aledort LM, Alvord WG, Goedert JJ. HIV-1 infection incidence among persons with hemophilia in the United States and Western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1994; 7.279-86
Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992; 11.167-78
Read CB. Fieller's theorem. In: Kotz S, Johnson NL, eds. Encyclopedia of Statistical Sciences. v 3. New York: Wiley; 1983:86-8.
Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. 2d ed. Norwalk, CT: Appleton & Lange; 1994:52-187.
O'Brien TR, Rosenberg PS, Yellin F, Goedert JJ. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18.155-61
Lyles R, Munoz A, Bazmi H, Yamashita T, Detels R, Rinaldo C, et al. Natural history of HIV-1 viremia after seroconversion in the Multicenter AIDS Cohort Study [Abstract]. Sixth Conference on Retroviruses and Opportunistic Infections, 31 January-4 February 1999, Chicago.
Chaturvedi S, Frame P, Newman SL. Macrophages from human immunodeficiency virus-positive persons are defective in host defense against Histoplasma capsulatum. J Infect Dis. 1995; 171.320-7
Harrison TS, Kornfeld H, Levitz SM. The effect of infection with human immunodeficiency virus on the anticryptococcal activity of lymphocytes and monocytes. J Infect Dis. 1995; 172.665-71
Maas JJ, Roos MT, Keet IP, Mensen EA, Krol A, Veenstra J, et al.. In vivo delayed-type hypersensitivity skin test anergy in human immunodeficiency virus type 1 infection is associated with T cell nonresponsiveness in vitro. J Infect Dis. 1998; 178.1024-9
Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, et al.. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998; 4.953-6
Wagner RP, Levitz SM, Tabuni A, Kornfeld H. HIV-1 envelope protein (gp120) inhibits the activity of human bronchoalveolar macrophages against Cryptococcus neoformans. Am Rev Respir Dis. 1992; 146.1434-8
Shiratsuchi H, Johnson JL, Toossi Z, Ellner JJ. Modulation of the effector function of human monocytes for Mycobacterium avium by human immunodeficiency virus-1 envelope glycoprotein gp120. J Clin Invest. 1994; 93.885-91
Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1992; 41(RR-4):1-11.
Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, et al.. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med. 1999; 130.570-7
Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al.. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999; 353.863-8